secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-08-10T11:15:25+00:00
Accession:  0001493152-26-036740
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix Q2 2026: TONMYA net sales $11M (+197% QoQ), net loss $40.6M
-----------------------------------------------------------------

- TONMYA net sales ~$11M, up 197% QoQ; total net product revenue $13.5M vs $2.0M year ago.
- Net loss $40.6M ($2.44/share) vs $28.3M ($3.86/share) in Q2 2025; cash $176.2M at June 30.
- First patient enrolled in Phase 2 HORIZON study of TNX-102 SL for MDD; ~360 patients planned.
- TNX-4800 Phase 2 Lyme prevention study on track to start Q1 2027 pending FDA agreement.
- Sales force to expand to ~150 reps by September; payer coverage ~136M lives (43% U.S.).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/0001493152-26-036740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226036740/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer